Amylyx Q3 2026 Earnings: Avexitide Progress Drives Higher Spending

Amylyx Pharmaceuticals (NASDAQ: AMLX) reported a Q3 2026 net loss of $45.5 million, or $0.38 per basic and diluted share, compared with $34.4 million, or $0.37 per share, a year earlier; quarterly revenue was not provided in the release. Higher research and pre-commercial spending widened the loss, while positive Phase 3 LUCIDITY results and a public offering that generated approximately $544.6 million moved avexitide’s regulatory and launch preparations to the center of the quarter.

Core Financial Results

Financial performance for the quarter ended September 30, 2026, reflected increased investment in clinical development and launch readiness. R&D expense rose primarily because of the pivotal LUCIDITY trial and other spending on avexitide and additional programs, partially offset by lower spending on the discontinued AMX0035 program for progressive supranuclear palsy.

SG&A increased because of personnel costs supporting pre-commercial activities and the vesting of performance stock unit awards. Combined stock-based compensation within R&D and SG&A was approximately $10.4 million, up from $7.0 million a year earlier. Higher other income partially offset the operating loss.

Avexitide Progress Is Driving Both R&D and Prelaunch Costs

The principal operating development was the positive topline result from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. The trial met its prespecified primary endpoint, showing a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo, with a p-value of 0.000003. Amylyx also said all secondary endpoints were met and avexitide was generally well tolerated during the double-blind period.

These results help explain the simultaneous increases in R&D and SG&A. Amylyx continued funding LUCIDITY and other avexitide work while building commercial capabilities ahead of a possible 2027 launch, subject to FDA approval. During the quarter, it completed its commercial leadership team and added personnel across marketing, market access, patient services and commercial operations.

The 32-week open-label extension of LUCIDITY and an expanded-access program remain ongoing. Amylyx said it remained on track to submit a New Drug Application for avexitide by the end of 2026.

Other Pipeline Programs and Upcoming Milestones

Beyond avexitide, Amylyx completed enrollment of the 12-participant third cohort in the Phase 1 LUMINA trial of AMX0114 and began enrolling the fourth cohort. AMX0114 is an investigational antisense oligonucleotide targeting calpain-2 for ALS and has FDA Fast Track designation. The company also continued IND-enabling work for AMX0318, a long-acting GLP-1 receptor antagonist candidate.

At the time of the earnings release, the company’s nearest disclosed milestones were concentrated in avexitide’s regulatory program, with additional development work planned for AMX0318.

Liquidity and Capital Structure

Cash, cash equivalents and marketable securities reached $768.1 million at September 30, 2026, up approximately $517.3 million from $250.8 million at June 30. The balance included approximately $544.6 million of net proceeds from the August 2026 public offering.

Amylyx ended the quarter with total assets of $786.8 million, total liabilities of $33.1 million and stockholders’ equity of $753.7 million. The financing strengthened liquidity ahead of the planned NDA submission and possible commercialization, but it also increased the share base. Weighted-average basic and diluted shares rose approximately 27.4% to 118.9 million from 93.3 million a year earlier, helping explain why the per-share loss changed only slightly even as the total net loss widened by 32.3%.

Recent Insider Transactions

Six of the 10 most recent reported insider transactions were sales, including five transactions reported on September 10, 2026. The remaining entries consisted of three zero-price stock grants and one derivative-security exercise or conversion; all were reported as direct holdings.

Separately, the six-month aggregate data showed seven purchases totaling 240,776 shares and seven sales totaling 151,302 shares, producing net purchases of 89,474 shares. Total insider holdings were reported at approximately 7.97 million shares. The aggregate figures and the latest transaction list cover different reporting slices, and the disclosed transactions do not establish the insiders’ reasons for trading.

Risks Investors Need to Watch

• Regulatory execution: Positive LUCIDITY results support the planned NDA, but the submission still must be completed and avexitide remains subject to FDA review and approval.
• Spending ahead of commercialization: R&D and SG&A both increased as Amylyx funded development and built commercial capabilities before receiving approval or launching avexitide.
• Early-stage pipeline uncertainty: AMX0114 remains in Phase 1, while AMX0318 is still undergoing IND-enabling work. Delays or unfavorable findings could alter the disclosed development timelines.
• Equity dilution: The public offering substantially increased liquidity, but the higher weighted-average share count affects per-share results and remains an important part of the capital structure.

Summary

Amylyx’s Q3 2026 results were defined by positive Phase 3 avexitide data, higher development and prelaunch spending, and a much larger cash position following the public offering. The next operating tests are the planned avexitide NDA submission, the regulatory process and the company’s ability to translate its commercial-readiness investment into an effective launch if approved, while continuing to advance its earlier-stage pipeline.